Bio Blast Pharma Ltd (NASDAQ:ORPN) is up by 10.12%, mainly driven by positive interim results from a Phase 2 open label clinical study of lead compound Cabaletta (IV trehalose) in 25 patients with oculopharyngeal muscular dystrophy (OPMD). Bio Blast said that the drug managed to improve the muscle function in patients and reduced difficulty in swallowing. It now plans to discuss the results from the Phase 2 study and a new mid-stage trial with the US Food and Drug Administration.
The stock of the specialty pharmaceutical company, Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has advanced by 16.51% on the back of robust quarterly results reported by the company, which included earnings of $0.35 per share, outperforming the consensus estimate of $0.20, and revenue of $62.20 million compared to the Street’s expectations of $60.44 million. The company reported a 19.6% revenue growth year-on-year, while EPS increased from $0.14 in the same quarter of 2014. A total of 25 funds among those we track disclosed long positions in Pacira in the previous round of 13F filings, while the aggregate value of their holdings being equal to 14% of the company’s outstanding stock.
Franklin Electric Co. (NASDAQ:FELE) has announced its quarterly earnings as well, beating the EPS estimates, but missing on the revenue side. As a result, the stock has gained around 16%. The company posted EPS of $0.45 for the quarter, compared with analysts’ consensus estimate of $0.41, while revenue of $232.5 million missed the estimates of $248.03 million. The revenue fell by 16.4% year-on-year, driven by a stronger dollar and lower oil prices. At the end of June, 12 funds from our database held shares of Franklin Electric Co. (NASDAQ:FELE).